Therapy Detail

Therapy Name Vorinostat
Therapy Description

Zolinza (vorinostat) inhibits HDAC activity, resulting in cell-cycle arrest, decreased proliferation, and increased differentiation of tumor cells (PMID: 9501205, PMID: 11731433, PMID: 11016644). Zolinza (vorinostat) is FDA approved for use in cutaneous T-cell lymphoma (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Vorinostat Zolinza SAHA|L-001079038|MSK390 HDAC Inhibitor 34 Zolinza (vorinostat) inhibits HDAC activity, resulting in cell-cycle arrest, decreased proliferation, and increased differentiation of tumor cells (PMID: 9501205, PMID: 11731433, PMID: 11016644). Zolinza (vorinostat) is FDA approved for use in cutaneous T-cell lymphoma (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
MYD88 L265P diffuse large B-cell lymphoma sensitive Vorinostat Preclinical - Cell culture Actionable In a preclinical study, a diffuse large B-cell lymphoma cell line harboring MYD88 L256P demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased apoptosis (PMID: 27733371). 27733371
EZH2 Y641S diffuse large B-cell lymphoma sensitive Vorinostat Preclinical Actionable In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023). 25605023
FBXW7 R505C head and neck squamous cell carcinoma sensitive Vorinostat Preclinical Actionable In a preclinical study, Zolinza (vorinostat) inhibited growth of a head and neck squamous cell carcinoma cell line harboring FBXW7 R505C in culture (PMID: 23274910). 23274910
Unknown unknown epithelioid sarcoma not applicable Vorinostat Preclinical Actionable In a preclinical study, Zolinza (vorinostat) inhibited growth and colony formation of epithelioid sarcoma cells in culture (PMID: 26396249). 26396249
Unknown unknown neuroblastoma not applicable Vorinostat Preclinical - Cell line xenograft Actionable In a preclinical study, Zolinza (vorinostat) displayed efficacy in human neuroblastoma cell lines in culture and in xenografts, including those resistant to Adriamycin (doxorubicin) (PMID: 22703804). 22703804
EZH2 Y641N diffuse large B-cell lymphoma sensitive Vorinostat Preclinical Actionable In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023). 25605023
RB1 loss retinoblastoma sensitive Vorinostat Preclinical - Cell culture Actionable In a preclinical study, Zolinza (vorinostat) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719). 23498719 18483379
TP53 L194F breast cancer sensitive Vorinostat Preclinical - Cell line xenograft Actionable In a preclinical study, Zolinza (vorinostat) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011). 26009011
Unknown unknown colon cancer not applicable Vorinostat Preclinical Actionable In a preclinical study, Zolinza (vorinostat) decreased the growth of colon tumors in mice, and this effect was enhanced by co-administration of Lipitor (atorvastatin) (PMID: 22161747). 22161747
Clinical Trial Phase Therapies Title Recruitment Status
NCT03259503 Phase Ib/II Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas Not yet recruiting
NCT03263936 Phase I Vorinostat Decitabine Cytarabine Fludarabine Filgrastim Epigenetic Reprogramming in Relapse/Refractory AML Recruiting
NCT01593670 Phase II Decitabine Aldesleukin Vorinostat Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes Terminated
NCT02420613 Phase I Vorinostat Temsirolimus Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG) Recruiting
NCT02589145 Phase Ib/II Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Active, not recruiting
NCT03022565 Phase I Vorinostat Vorinostat in Patients With Class 2 High Risk Uveal Melanoma Recruiting
NCT01587352 Phase II Vorinostat Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Terminated
NCT00719875 Phase Ib/II Vorinostat HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer Completed
NCT01193842 Phase Ib/II Vorinostat R-EPOCH Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Active, not recruiting
NCT01339871 Phase I Vorinostat Pazopanib Phase I Study of Pazopanib and Vorinostat Completed
NCT02788201 Phase II Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifine Crizotinib Dactinomycin Temsirolimus Vorinostat romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Recruiting
NCT02553460 Phase II Cyclophosphamide Mitoxantrone Dexamethasone Bortezomib Etoposide Vincristine Pegaspargase Vorinostat Cytarabine Methotrexate Leucovorin Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I Recruiting
NCT02083250 Phase I anti-thymocyte globulin Vorinostat Busulfan + Clofarabine + Fludarabine Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia Active, not recruiting
NCT03117751 Phase II Cyclophosphamide Vincristine Idarubicin Blinatumomab Doxorubicin Clofarabine Vorinostat Ruxolitinib Prednisone Bortezomib Etoposide Dasatinib Daunorubicin Dexamethasone Rituximab Methotrexate Cytarabine Mercaptopurine Pegaspargase Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting
NCT02412475 Phase I Cytarabine Sorafenib Vorinostat Filgrastim Daunorubicin Fludarabine Decitabine Epigenetic Reprogramming in Relapse AML Active, not recruiting
NCT01879085 Phase Ib/II Gemcitabine Docetaxel Pegfilgrastim Vorinostat Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Recruiting
NCT02137759 Phase II Vorinostat Temozolomide MRSI to Predict Response to RT/TMZ and Vorinostat in GBM Recruiting
NCT02316340 Phase II Vorinostat Hydroxychloroquine Regorafenib Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer Recruiting
NCT02559778 Phase I Bortezomib Crizotinib Lapatinib Vorinostat Eflornithine Sorafenib Dasatinib Pediatric Precision Laboratory Advanced Neuroblastoma Therapy Recruiting
NCT01059552 Phase I Vorinostat Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
NCT01281176 Paclitaxel Vorinostat Carboplatin High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors Active, not recruiting
NCT01087554 Phase I Temsirolimus Everolimus Sirolimus Vorinostat Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer Active, not recruiting
NCT01064921 Phase I Cisplatin Vorinostat Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma Completed
NCT02638090 Phase Ib/II Pembrolizumab Vorinostat Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) Recruiting
NCT01249443 Phase I Carboplatin Vorinostat Paclitaxel Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Terminated
NCT02108002 Vorinostat Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) Completed
NCT02419755 Phase II Cytarabine Mercaptopurine Methotrexate Pegaspargase Vorinostat Doxorubicin Bortezomib Dexamethasone Mitoxantrone Prednisone Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Terminated
NCT01790568 Phase II Methotrexate Tacrolimus Vorinostat Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant Completed